HomeNewsAutomobileMaruti Suzuki rolls out 1,65,576 units in June

Maruti Suzuki rolls out 1,65,576 units in June

MSI has shut production from May 1 till May 16 in order to divert oxygen from industrial use for medical purposes.

July 05, 2021 / 23:10 IST
Story continues below Advertisement
Maruti Suzuki India | Representative image
Maruti Suzuki India | Representative image

The country's largest carmaker Maruti Suzuki India (MSI) on Monday said its total production last month rose to 1,65,576 units as various states eased COVID related restrictions. The company had produced a total of 40,924 units in May this year, Maruti Suzuki India (MSI) said in a regulatory filing.

MSI has shut production from May 1 till May 16 in order to divert oxygen from industrial use for medical purposes. Production of mini cars comprising Alto and S-Presso models stood at 26,316 units last month as against 4,896 units in May.

Story continues below Advertisement

ALSO READ: Maruti Suzuki dispatches to dealerships jump to 1,47,368 units in June

Manufacturing of compact cars, comprising WagonR, Celerio, Ignis, Swift, Baleno and Dzire, rose to 89,966 units last month as against 25,130 units in May 2021, MSI said. Similarly, production of utility vehicles — Gypsy, Ertiga, S-Cross, Vitara Brezza and XL6 — increased to 35,917 units in June as compared with 9,106 units in May.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show